共 122 条
[1]
Pao W(2010)Rational, biologically based treatment of Nat Rev Cancer 10 760-74
[2]
Chmielecki J(2017)-mutant non-small-cell Lung cancer Cancer Discov 7 596-609
[3]
Jordan EJ(2004)Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies Cancer Res 64 8919-23
[4]
Kim HR(2018)Mutations of the epidermal growth factor receptor gene in Lung cancer: biological and clinical implications N Engl J Med 378 113-25
[5]
Arcila ME(2012)Osimertinib in untreated EGFR-mutated advanced non-small-cell Lung cancer Lancet Oncol 13 239-46
[6]
Barron D(2010)Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced Lancet Oncol 11 121-8
[7]
Chakravarty D(2013) mutation-positive non-small-cell Lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial J Clin Oncol 31 3327-34
[8]
Gao J(2019)Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell Lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Br J Cancer 121 725-37
[9]
Kosaka T(2018)Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations Ann Oncol 29 viii740-63
[10]
Yatabe Y(2023)Resistance mechanisms to osimertinib in Nat Commun 14 1071-9